

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/58, 31/57, 31/565</b>	<b>A1</b>	(11) International Publication Number: <b>WO 98/04269</b>
		(43) International Publication Date: 5 February 1998 (05.02.98)

(21) International Application Number: PCT/US97/12795  
(22) International Filing Date: 23 July 1997 (23.07.97)  
(30) Priority Data:  
08/686,790 26 July 1996 (26.07.96) US

(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventor: GAST, Michael, Jay; 230 Country Lane, Phoenixville, PA 19460 (US).

(74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published**

*With international search report.*

*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: MONOPHASIC CONTRACEPTIVE METHOD AND KIT COMPRISING A COMBINATION OF A PROGESTIN AND ESTROGEN

(57) Abstract

This invention provides a method of contraception which comprises administering to a female of child bearing age for a combination of a progestin at a daily dosage of 40-500  $\mu$ g trimegestone, 250  $\mu$ g - 4 mg dienogest, or 250  $\mu$ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20  $\mu$ g ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle, and wherein the same dosage of the progestin and estrogen combination is administered in each of the 23-25 days.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

## MONOPHASIC CONTRACEPTIVE METHOD AND KIT COMPRISING A COMBINATION OF A PROGESTIN AND ESTROGEN

## BACKGROUND OF THE INVENTION

5       The vast majority of oral contraceptives consist of a combination of a progestin and estrogen that are administered concurrently for 21 days followed either by a 7 day pill free interval or by the administration of a placebo for 7 days in each 28 day cycle. The most important aspects of a successful oral contraceptive product are effective  
10       contraception, good cycle control (absence of spotting and breakthrough bleeding and occurrence of withdrawal bleeding), and minimal side effects. Combination oral contraceptives have traditionally acted by suppression of gonadotropins. In addition, it appears that the progestin component is primarily responsible for contraceptive efficacy through inhibition of ovulation, and other peripheral effects which include changes in  
15       the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). The estrogenic component intensifies the anovulatory effect of the progestin, and is also important for maintaining cycle control.

      Since the introduction of oral contraceptives (OCs) over a quarter-century ago, research has been directed toward developing preparations that minimize the potential  
20       for side effects while maintaining efficacy and normal menstrual patterns. The first-generation OCs contained more progestin and estrogen than was necessary to prevent conception. Adverse hemostatic and metabolic changes, clinical problems, and side effects were associated with these high-dose preparations. In 1978, the World Health Organization (WHO) recommended that the focus of OC research should be the  
25       development of products containing the lowest possible dose levels of estrogen and progestin.

      The first reductions in steroid content in a combination pill were focused on estrogen because it, rather than progestin, was thought to be related to the most serious side effects. Reduction in progestin content followed, as evidence mounted that  
30       lowering progestin intake might lower the risk of cardiovascular complications such as stroke and ischemic heart disease. [Kay CR, Am J Obstet Gynecol 142:762 (1982)]. However, this evidence was not as clear as that implicating estrogen in thromboembolic disorders. [Inman WHW, Br Med J 2:203 (1970); Stolley PD, Am J Epidemiol 102:197 (1975)]. The need for a balance between estrogens and progestins to minimize  
35       adverse effects on carbohydrate metabolism and on lipid and lipoprotein levels was also recognized. [Bradley DD, N Engl J Med 299:17 (1978); Wynn V, Lancet 1:1045

- 2 -

(1979)]. Researchers then found that the synergistic action between progestin and estrogen in a balanced ratio successfully inhibited ovulation at low levels of both components.

5 Research into low-dose progestins was advanced significantly by the development of norgestrel (Ng) and levonorgestrel (LNg). Levonorgestrel is the biologically active moiety of racemic norgestrel. It is strongly progestational, has no inherent estrogenic activity, is antiestrogenic, and possesses good biologic activity. The contraceptive effects of levonorgestrel are manifested throughout the hypothalamic-pituitary-gonadal-target organ axis.

10 Ethinyl estradiol (EE) is the estrogen most frequently used in combination OCs. In attempts to fulfill the WHO objective, the dosage of EE in marketed OC formulations has been steadily reduced from that found in earlier OCs. Thromboembolic mortality decreased when the amount of synthetic estrogen in OC formulations was reduced from 100 µg to 50 µg. Subsequently, a significant reduction in fatal myocardial infarctions  
15 was reported for women using OCs with 30 µg of EE rather than 50 µg of EE. [Meade TW, Br Med J 280:1157 (1980)].

In keeping with the goal of reducing the total steroidal dosage, while maintaining contraceptive efficacy, good cycle control, and minimizing side effects, numerous regimens have been developed in which the progestin/estrogen combination  
20 is administered either as a fixed dosage combination (monophasic) or as biphasic or triphasic regimens in which the dosage of the combination is varied either once or twice throughout the menstrual cycle. In these regimens, the progestin/estrogen combination is typically administered for 21 days followed by either a 7-day pill free period or the administration of a non-contraceptive placebo (or iron supplement) for 7 days. In these  
25 regimens, 3-ketodesogestrel (3-KDSG), desogestrel (DSG), levonorgestrel (LNg), gestodene (GTD), norgestrel (NG), and norethindrone (NE) are typically used as the progestin while ethinyl estradiol (EE); 17β-estradiol, and mestranol are typically the estrogenic components. Other progestins less frequently used include drospirenone (DRSP) and dienogest (DGST).

30 An oral contraceptive product containing a combination of 3 mg DGST and 30 µg EE for 21-day administration per cycle is marketed in Germany.

Several examples of attempts at reducing the total steroidal dosage are provided below.

35 Spona (PCT Publication WO 95/17194) discloses contraceptive regimens which consist of the administration of a combination of a progestin (50 - 75 µg GTD, 75 - 125 µg LNg, 60 - 150 µg DSG, 60 - 150 µg 3-KDSG, 100 - 300 µg DRSP, 100 - 200 µg

- 3 -

cyproterone acetate, 200 - 300 µg norgestimate, or >350 - 750 µg norethisterone) and an estrogen (15 - 20 µg EE or 2 - 6 mg 17β-estradiol) for 23-24 days per cycle.

5 Oettel (EP 628,312 A1) discloses combination contraceptive combinations containing the combination of three components: a biogenic estrogen (estradiol, estrone, or estriol), a synthetic estrogen (EE or mestranol), and a progestin (LNg, desogestrel, progesterone, norethisterone acetate, DGST, chlormadinone acetate, gestodene, or cyproterone acetate). In one embodiment, the combination is administered for 21 days followed by the administration of placebo (or pill free) or an estrogen on days 22-28 of the cycle.

10 Oettel (EP 696,454 A2) discloses a three phase contraceptive regimen in which the first phase consists of the administration for 3-4 days of a composition containing at least one biogenic estrogen; the second phase consists of the administration for 20-22 days of at least one biogenic estrogen and at least one progestin (progesterone, DGST, desogestrel, 3-KDSG, GTD, LNg, norgestimate, norethisterone, norethisterone acetate, 15 dehydrogestrone, chloromadinone acetate, cyproterone acetate, medroxyprogesterone acetate, or megestrol acetate); and the third phase consists of the administration for 3-4 days of a composition containing at least biogenic one estrogen.

Lachnit (PCT Publication WO 95/26730) discloses bridged regimens consisting of the administration of a combination of a progestin/estrogen combination (50 - 125 µg 20 LNg and 10 - 40 µg EE) for the first 23-24 days of the menstrual cycle followed by the administration of an estrogen (2 - 40 µg EE) for 4-10 days for a total administration of at least 28 days per cycle. The use of 100 - 300 µg drospirenone and 10 - 40 µg EE as the 23-24 day progestin/estrogen combination is disclosed. Lachnit also discloses a triphasic plus bridging regimen (4-9 days, 4-9 days, 9-13 days, and 28 days for the 25 three phases and estrogen phase, respectively) in which a combination of 50 µg LNg and 20 µg EE are administered in the first phase, a combination of 75 µg LNg and 25 µg EE are administered in the second phase, a combination of 100 µg LNg and 20 µg EE are administered in the third phase, and 10 µg EE is administered in the estrogen phase. Other progestins disclosed include GTD, DSG, 3-KDSG, DRSP, cyproterone 30 acetate, norgestimate, and norethisterone.

Upton (EP Patent Specification 253,607 B1) teaches the use of low dose progestin/estrogen combinations for combined hormone replacement therapy and contraception in climacteric women. Climacteric women are defined in Upton as premenopausal women around 40 years of age whose hormone levels are waning. The 35 climacteric woman still ovulates (albeit may have irregular ovulation), but she still

- 4 -

experiences many of the symptoms of the hypoestrogenic menopausal woman, such as insomnia, hot flushes, and irritability. Upton teaches the administration of a 23-26 day monophasic regimen of progestin/estrogen followed by a pill free or placebo interval of 2-5 days; with 24 days of progestin/estrogen administration followed by a 4-day pill free or placebo administration being preferred. Upton teaches the use of a progestin selected from 25 - 100 µg LNg, 10 - 70 µg GTD, 25 - 100 µg DSG, 25 - 100 µg 3-KDSG, and 85 - 350 µg NE used in combination with an estrogen selected from 500 - 2000 µg 17β-estradiol, 8 - 30 µg EE, and 15 - 60 µg mestranol. Based on relative potencies, Upton teaches that a dose of 75 µg LNg is equivalent to 35 µg of GTD, 75 µg of 3-KDSG or DSG, and 250 µg NE and that a dose of 1000 µg of 17β-estradiol is equivalent to a dose of 15 µg EE and 30 µg mestranol. Upton also teaches that NG may be substituted for LNg, but at twice the dose.

Sartoretto (Clinica e Terapeutica 3: 399 (1974)) discloses a monophasic contraceptive regimen consisting of the administration of a combination 100 µg LNg and 20 µg EE for 21 days.

Lachnit-Fixson (U.S. Patent 3,969,502) discloses biphasic progestin/estrogen combination regimens in which a combination of 50-125 µg LNg and 25-35 µg EE are administered for 10-12 days in the first phase and 100-350 µg LNg and 30-50 µg EE are administered for 10-12 days in the second phase. Placebo is administered for 5-7 days following the administration of the contraceptive steroid regimen.

Lachnit-Fixson (U.S. Patent 3,957,982) discloses triphasic 21-day progestin/estrogen regimens in which a combination of 40-90 µg LNg and 20-50 µg EE is administered for 4-6 days in the first phase, 50-125 µg LNg and 30-50 µg EE is administered for 4-6 days in the second phase, and 100-250 µg LNg and 25-50 µg EE is administered for 9-11 days in the third phase. It is preferred that the first, second, and third phases are 6, 5, and 10 days, respectively.

Bennick (U.S. Patent 5,418,228) discloses triphasic regimens which consist of the administration of a combination progestin/estrogen in a 6-8 day phase, a second 6-8 day phase, and a third 6-8 day phase, with it being preferred that the three contraceptive steroid phases be 7 days each. Bennick discloses that the first contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 150 µg DSG and an estrogen at a daily dosage equivalent to 20 - 25 µg EE; the second contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 125 µg DSG and an estrogen at a daily dosage equivalent to 20 µg EE; and the third contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 100 µg DSG and an estrogen at a daily dosage equivalent to 20 µg EE. Placebo is administered for 7

- 5 -

days following the 21-day contraceptive steroid period. Bennick discloses that the progestin may be 3-KDSG, DSG, LNg, or GTD.

5 Bergink (U.S. Patent 5,262,408) discloses a 24 day triphasic combination regimen in which the first 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 100 µg DSG and an estrogen at a daily dosage equivalent to 25 µg EE, the second 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 125 µg DSG and an estrogen at a daily dosage equivalent to 20 µg EE, and the third 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 50 µg DSG and an estrogen at a daily dosage equivalent to 10 20 µg EE. It is preferred that the three phases be 8 days each. Following the 24 day contraceptive steroid administration, a placebo may be administered for 4 days, the 4 day interval may be pill free, or a progestin at a dosage equivalent to 25-35 µg DSG may be administered.

15 Boissonneault (U.S. Patent 4,962,098) discloses triphasic progestin/estrogen combinations in which the amount of the estrogenic component is increased stepwise over the three phases. Contraceptive steroid combinations are taken for 4-7 days during the first phase (5 days being preferred); for 5-8 days during the second phase (7 days preferred); and for 7-12 days during the third phase (9 days being preferred). Following the administration of 21-days of the contraceptive steroid combination, 20 placebo is taken for 7 days. For all three phases, 0.5-1.5 mg of norethindrone acetate is used in the progestin, with 1 mg being preferred. 10-30 µg EE is used in the first phase, 20-40 µg in the second, and 30-50 µg in the third phase.

25 Pasquale (U.S. Patent 4,921,843) discloses combination progestin/estrogen contraceptive regimens which contain 0.5 to 1 mg of progestin and an estrogen having a dose equivalent to 10-40 µg of EE. NE, LNg, D-17β-acetoxy-13β-ethyl-17α-ethinylgon-4-en-3-one oxime, and 19-nor-17-hydroxy progesterone ester are disclosed as progestins, with NE being preferred. Specifically disclosed regimens include a uniphasic regimen (2 days of placebo, 5 days of 20 µg EE, and 21 days of a combination of 500 µg NE and 35 µg EE); a uniphasic regimen (2 days of placebo, 5 30 days of 40 µg EE, and 21 days of a combination of 500 µg NE and 35 µg EE); and a triphasic regimen (2 days of placebo; 5 days of 20-40 µg EE; 7 days of a combination of 500 µg NE and 35 µg EE; 7 days of a combination of 750 µg NE and 35 µg EE; and 7 days of a combination of 1 mg NE and 35 µg EE).

35 Pasquale (U.S. Patent 4,628,051) discloses triphasic progestin/estrogen combination regimens in which contraceptive steroid is administered for 21 days. Contraceptive steroid combinations are taken for 5-8 days during the first phase (7 days

- 6 -

being preferred); for 7-11 days during the second phase (7 days preferred); and for 3-7 days during the third phase (7 days being preferred). In all three phases, an estrogen at a daily dosage equivalent to 20-50  $\mu$ g EE is administered in combination with a progestin having a daily dosage equivalent to 65-750  $\mu$ g NE in the first phase, 0.25-1.0 mg NE in the second phase, and 0.35-2.0 mg NE in the third phase. A specific triphasic regimen discloses the administration of 35  $\mu$ g EE in each of the three 7-day phases in combination with 0.5 mg, 0.75 mg, and 1.0 mg in the first, second, and third phases, respectively. A second specific triphasic regimen discloses the administration of 35  $\mu$ g EE in each of the three 7-day phases in combination with 50  $\mu$ g, 75  $\mu$ g, and 100  $\mu$ g in the first, second, and third phases, respectively. A third specific triphasic regimen discloses the administration of 35  $\mu$ g EE in each of the three 7-day phases in combination with 25  $\mu$ g, 35  $\mu$ g, and 50  $\mu$ g in the first, second, and third phases, respectively.

Lachnit-Fixson (U.S. Patent 4,621,079) discloses triphasic 21-day progestin/estrogen combination regimens in which a combination of 40-70  $\mu$ g GTD and 20-35  $\mu$ g EE is administered for 4-6 days in the first phase; 50-100  $\mu$ g GTD and 30-50  $\mu$ g EE is administered for 4-6 days in the second phase; and 80-120  $\mu$ g GTD and 20-50  $\mu$ g EE is administered for 9-11 days in the third phase. Placebo is administered for 7 days following the 21-day contraceptive steroid regimen.

Pasquale (U.S. Patent 4,530,839) discloses triphasic 21-day progestin/estrogen combination regimens in which a dose of 20-50  $\mu$ g EE is administered in all three phases in combination with a contraceptively effective daily dose of progestin in the first phase, 1.5-2 times that dose of progestin in the second phase, and 2-2.5 times the first phase dose of progestin in the third phase. Each of the three phases is 7 days long. A specific regimen discloses 20-50  $\mu$ g EE in combination with 500  $\mu$ g LNg, 750  $\mu$ g LNg, and 1 mg LNg during each of the three 7-day phases, respectively.

Edgren (U.S. Patent 4,390,531) discloses triphasic 21-day progestin/estrogen combination regimens in which a dose of 20-40  $\mu$ g EE (or another estrogen in an equivalent dosage) is administered in all three phases in combination with 0.3-0.8 mg NE (or another progestin in an equivalent dosage) for 5-8 days in the first phase, twice the dose of NE for 7-11 days in the second phase, and the dose of NE being the same as in the first phase for 3-7 days in the third phase. It is preferred that each of the three phases is 7 days. Placebo is administered for 6-8 days following administration of the contraceptive steroid combination. A specific regimen discloses a first phase of 7 days of 0.5 mg NE in combination with 35  $\mu$ g EE, a second 7 day phase of 1.0 mg NE in



- 7 -

combination with 35 µg EE, and a third 7 day phase of 0.5 mg NE in combination with 35 µg EE.

Moore (DE 4313926 A1) discloses bridged triphasic regimens consisting of the administration of a combination of 10 - 50 µg LNg and 5 - 20 µg EE from days 1-7 of the menstrual cycle; of 50 - 75 µg LNg and 5 - 20 µg EE from days 8-14 of the menstrual cycle; of 75 - 125 µg LNg and 5 - 20 µg EE from days 15-21 of the menstrual cycle; and 5 - 20 µg EE from days 22-28 of the menstrual cycle.

Erlich (German Patent DE 4,104,385 C1 and U.S. Patent 5,280,023) discloses sequential contraceptive regimens consisting of the administration of an estrogen which effects a disturbance of follicle stimulation, followed by the administration of a combination of a progestin/estrogen in a dose at least adequate to inhibit ovulation. The regimen is administered for a total of 28 days per cycle. It is preferred that the estrogen is administered for 5-14 days per cycle and the progestin/estrogen combination is administered for 23-14 days per cycle, so that the total administration is for 28 days per cycle. Specific regimens include (a) 4 mg estradiol for 7 days followed by 21 days of the combination of 1 mg norethisterone acetate and 4 mg estradiol; (b) 2 mg estradiol valerate for 7 days followed by 21 days of the combination of 2 mg chlormadinone acetate and 4 mg estradiol valerate; and (c) 20 µg EE followed by 18 days of the combination of 150 µg LNg and 20 µg EE. Regimen (c) in Erlich provides a total steroidal load of 2.7 mg of LNg and 560 µg EE per 28 day cycle.

## DESCRIPTION OF THE INVENTION

This invention provides a monophasic combination progestin/estrogen oral contraceptive regimen for females of child-bearing age that provides effective contraception, good cycle control, and minimal side effects while greatly reducing the total contraceptive steroid administered (particularly the estrogenic component) per 28-day cycle. To achieve the substantial reduction in the total contraceptive steroid administered per cycle while maintaining good cycle control, the low dose progestin/estrogen combination is administered for 23-25 days per cycle. Administration of the contraceptive progestin/estrogen combination is begun on the first day of menses (day 1), and continued for 23-25 consecutive days. Following the 23-25-day administration period, a non-contraceptive placebo (devoid of progestins and estrogens) can be provided for 3-5 days to aid in compliance with the desired

- 8 -

contraceptive regimen. Alternatively, the 3-5-day interval can be pill free. The total cycle length is 28 days.

More particularly, this invention provides a method of contraception which comprises administering to a female of child bearing age a combination of 40-500 µg  
 5 trimegestone, 250 µg - 4 mg dienogest, or 250 µg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle. Following the 23-25-day administration period, a non-contraceptive placebo (devoid of progestins and estrogens) can be provided for 3-5 days to aid in compliance with the desired contraceptive  
 10 regimen. Alternatively, the 3-5-day interval can be pill free. The total cycle length is 28 days.

Preferred estrogens include, but are not limited to ethinyl estradiol; 17β-estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol; with ethinyl estradiol being more preferred. When ethinyl estradiol is used as the estrogen, it  
 15 is preferred that the daily dosage of ethinyl estradiol is 10-20 µg, with 15 µg being more preferred. Preferred salts of estrone include, but are not limited to the sodium and piperate salt. When conjugated estrogens, USP are used as the estrogen, it is preferred that the daily dosage is 0.3-5 mg, with a daily dose of 1.25 mg conjugated estrogens, USP being equivalent to a daily dose of 15 µg ethinyl estradiol.

20 Following the 23-25-day period, a non-contraceptive placebo, which may contain an iron supplement, such as 75 mg of ferrous fumarate, may be administered for 4 days (through day 28 of the menstrual cycle) or the 4 days following administration of the contraceptive combination may be pill free.

It is preferred that the progestin/estrogen combination be administered for 24  
 25 days beginning on day 1 of the menstrual cycle.

The following daily dosages of a combination of trimegestone and ethinyl estradiol are preferred for contraception when administered for 23-25 consecutive days beginning on the first day of menses. Regimen B is most preferred.

30

## PREFERRED DAILY DOSAGES

Regimen	Trimegestone	Ethinyl Estradiol
A	250 µg	15 µg
B	125 µg	15 µg
C	75 µg	15 µg
35 D	50 µg	15 µg
E	40 µg	15 µg

- 9 -

The following daily dosages of a combination of dienogest and ethinyl estradiol are preferred for contraception when administered for 23-25 consecutive days beginning on the first day of menses. Regimen B is most preferred.

5

## PREFERRED DAILY DOSAGES

Regimen	Dienogest	Ethinyl Estradiol
A	2 mg	15 µg
B	1 mg	15 µg
10 C	800 µg	15 µg
D	750 µg	15 µg
E	500 µg	15 µg

15

The following daily dosages of a combination of drospirenone and ethinyl estradiol are preferred for contraception when administered for 23-25 consecutive days beginning on the first day of menses. Regimen C is most preferred.

20

## PREFERRED DAILY DOSAGES

Regimen	Drospirenone	Ethinyl Estradiol
A	3 mg	15 µg
B	2 mg	15 µg
C	1 mg	15 µg
25 D	500 µg	15 µg

25

It is preferred that the combination progestin/estrogen contraceptive be administered in unit dosage form i.e., tablet or pill, with each unit providing the entire daily dosage. It is preferred that the progestin and estrogen are admixed together in the same dosage unit. Such dosage units can be prepared by conventional methodology that is well known to one skilled in the art. In each dosage unit, the contraceptively active progestin and estrogen are combined with excipients, vehicles, pharmaceutically acceptable carriers, and colorants. For example, the following illustrates an acceptable composition of a contraceptive progestin/estrogen combination of this invention.

30

- 10 -

EXAMPLE 1

5 Trimegestone, 125 µg  
Ethinyl estradiol, 15 µg  
Microcrystalline Cellulose  
Lactose, NF, Spray Dried  
Polacrillin Potassium, NF  
Magnesium Stearate  
Opadry Pink  
10 Polyethylene Glycol, 1500, Flakes  
Water, Purified, USP  
Wax E (Pharma)

15 This invention also provides a contraceptive kit adapted for daily oral administration which comprises 23-25 separate dosage units, said dosage units each consisting of a combination of 40-500 µg trimegestone, 250 µg - 4 mg dienogest, or 250 µg - 4 mg mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinyl estradiol. In another embodiment, the  
20 contraceptive kit contains 28 daily dosage units with 3-5 being a non-contraceptive placebo, that may contain an iron supplement, such as 75 mg ferrous fumarate. The daily dosage arrangements are preferably arranged in a blister pack or in a dial pack type tablet dispenser.

- 11 -

## WHAT IS CLAIMED IS:

1. A method of contraception which comprises administering to a female of child bearing age a combination of a progestin at a daily dosage selected from the group consisting of 40-500  $\mu\text{g}$  trimegestone, 250  $\mu\text{g}$  - 4 mg dienogest, and 250  $\mu\text{g}$  - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20  $\mu\text{g}$  ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle, and wherein the same dosage of the progestin and estrogen combination is administered in each of the 23-25 days.
2. The method according to claim 1, wherein the estrogen is selected from the group consisting of ethinyl estradiol; 17 $\beta$ -estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol.
3. The method according to claim 2, wherein the estrogen is ethinyl estradiol.
4. The method according to claim 3, wherein the progestin/estrogen combination is administered for 24 days per menstrual cycle beginning on day 1 of the menstrual cycle.
5. The method according to claim 4 wherein the daily dosage of ethinyl estradiol is 15  $\mu\text{g}$ .
6. The method according to claim 5, wherein the progestin is trimegestone.
7. The method according to claim 6, wherein the daily dosage of trimegestone is 250  $\mu\text{g}$ .
8. The method according to claim 6, wherein the daily dosage of trimegestone is 125  $\mu\text{g}$ .
9. The method according to claim 6, wherein the daily dosage of trimegestone is 75  $\mu\text{g}$ .
10. The method according to claim 6, wherein the daily dosage of trimegestone is 50  $\mu\text{g}$ .

- 12 -

11. The method according to claim 6, wherein the daily dosage of trimegestone is 40 µg.

5 12. The method according to claim 5, wherein the progestin is dienogest.

13. The method according to claim 11, wherein the daily dosage of dienogest is 2 mg.

10 14. The method according to claim 11, wherein the daily dosage of dienogest is 1 mg.

15. The method according to claim 11, wherein the daily dosage of dienogest is 800 µg.

15

16. The method according to claim 11, wherein the daily dosage of dienogest is 750 µg.

20 17. The method according to claim 11, wherein the daily dosage of dienogest is 500 µg.

18. The method according to claim 5, wherein the progestin is drospirenone.

25 19. The method according to claim 18, wherein the daily dosage of drospirenone is 3 mg.

20. The method according to claim 18, wherein the daily dosage of drospirenone is 2 mg.

30 21. The method according to claim 18, wherein the daily dosage of drospirenone is 1 mg.

22. The method according to claim 18, wherein the daily dosage of drospirenone is 500 µg.

35

- 13 -

23. The method according to claim 1, which further comprises administering a non-contraceptive placebo for 3-5 consecutive days beginning on the day immediately following the last day of administration of the progestin/estrogen combination, such that the total days of administration of the progestin/estrogen combination plus the non-contraceptive placebo equals 28 days.

24. The method according to claim 23 in which the non-contraceptive placebo contains an iron supplement.

25. A contraceptive kit adapted for oral administration which comprises 23-25 separate dosage units, said dosage units each containing a combination of a progestin at a dosage selected from the group consisting of 40-500  $\mu$ g trimegestone, 250  $\mu$ g - 4 mg dienogest, and 250  $\mu$ g - 4 mg drospirenone, and an estrogen at a dosage equivalent in estrogenic activity to 10-20  $\mu$ g ethinyl estradiol, wherein each of the dosage units contains the same dosage of progestin and estrogen.

26. The contraceptive kit according to claim 25, wherein the estrogen is selected from the group consisting of ethinyl estradiol; 17 $\beta$ -estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol.

27. The contraceptive kit according to claim 26, wherein the estrogen is ethinyl estradiol.

28. The contraceptive kit according to claim 27 in which the number of dosage units is 24.

29. A contraceptive kit adapted for oral administration which comprises 28 dosage separate units, 23-25 of said dosage units each containing each containing a combination of a progestin at a dosage selected from the group consisting of 40-500  $\mu$ g trimegestone, 250  $\mu$ g - 4 mg dienogest, and 250  $\mu$ g mg drospirenone, and an estrogen at a dosage equivalent in estrogenic activity to 10-20  $\mu$ g ethinyl estradiol, wherein each of the dosage units contains the same dosage of progestin and estrogen; and 3-5 of said dosage units each containing a non-contraceptive placebo; wherein each of the 23-25 dosage units contains the same dosage of progestin and estrogen.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/12795

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 A61K31/58 A61K31/57 A61K31/565

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 17194 A (SCHERING AG) 29 June 1995  see abstract see page 4, paragraph 3 - page 6, paragraph 4; claims 1-3,6,7,9 ---	1-5, 18, 25-29
X	OELKERS W ET AL: "Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism." J CLIN ENDOCRINOL METAB, JUN 1995, 80 (6) P1816-21, UNITED STATES, XP002046619 see page 1816, column 1, paragraph 2 - column 2, paragraph 1 see page 1817, column 1, paragraph 1-4 see abstract --- -/--	1-4, 18, 19

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

14 November 1997

Date of mailing of the international search report

09/12/1997

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/12795

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 97 01342 A (SCHERING AG ; SCHMIDT GOLLWITZER KARIN (DE); KLEMMAN WALTER (DE)) 16 January 1997  see abstract; claims 2,8-10; example 1 ---	1-5, 12-14, 18-21, 25-29
X	DE 44 11 585 A (SCHERING AG) 5 October 1995  see abstract; claims 1-4; example 1 ---	1-5, 18-21, 25-29
X	OELKERS W K H: "Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure" STERIODS, 61 (4). 1996. 166-171., XP002046622 see abstract; figure 3; table 1 ---	1-5, 18, 19
A	OETTEL M. ET AL: "A 19-norprogesterin without 17alpha-ethinyl group II: Dienogest from a pharmacodynamic point of view" DRUGS OF TODAY, 1995, 31/7 (517-536), SPAIN, XP002046623 see the whole document ---	1-5, 12-17, 23-29
A	KUHL H.: "Current developments in hormonal contraception" GYNAKOLOGE, 1992, 25/4 (231-240), GERMANY, XP002046624 see page 232, column 1 see page 236, column 1, paragraph 3 see page 236, column 3, paragraph 3 - page 237, column 1, paragraph 1 -----	1-5, 23, 24

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/12795

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9517194 A	29-06-95	DE 4344462 A	29-06-95
		CA 2179728 A	29-06-95
		CN 1142185 A	05-02-97
		CZ 9601861 A	11-12-96
		EP 0735883 A	09-10-96
		HU 74877 A	28-02-97
		JP 9506888 T	08-07-97
		NO 962676 A	22-08-96
		PL 315168 A	14-10-96
		SK 83196 A	05-02-97
		US 5583129 A	10-12-96
WO 9701342 A	16-01-97	DE 19525017 A	02-01-97
		AU 6352896 A	30-01-97
DE 4411585 A	05-10-95	AU 2073595 A	23-10-95
		CZ 9602879 A	12-02-97
		WO 9526730 A	12-10-95
		EP 0750501 A	02-01-97
		FI 963831 A	29-11-96
		HU 75521 A	28-05-97
		NO 964089 A	07-11-96
		PL 316569 A	20-01-97
		SK 124396 A	07-05-97